ONLY DUPIXENT IS INDICATED FOR
OCS-DEPENDENT ASTHMA PATIENTS1
DUPIXENT directly inhibits IL-4 and IL-13 signaling, two of the key drivers of type 2 inflammation1,*
*The mechanism of action of dupilumab has not been definitively established.
Only DUPIXENT reduced or eliminated steroids while simultaneously
improving asthma control1,2
At Week 24 in the VENTURE study
86%
of patients reduced or
eliminated their OCS dose2,a
59%
reduced was observed
in severe exacerbation1,b,c
220 mL
improvement was
seen in lung function in
asthma patients who
required daily OCS2,d
No biomarker requirement, ITT population: Reduced or eliminated OCS dose and reduced severe exacerbation rates
and improved lung function (secondary endpoints) at Week 241,2,e-g
- 70% significant mean reduction in OCS dose (median 100%) from baseline at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) (95% CI: 60%,
80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint)1 - Effects on lung function and on oral steroid and exacerbation reduction were similar irrespective of baseline blood EOS levels. Subjects with
baseline blood EOS levels up to 1500 cells/μL were included1
a At Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107) in VENTURE.2
b At Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs placebo + SOC (n=107) (0.65 vs 1.60; rate ratio: 0.41 [95% CI: 0.26, 0.63]) in VENTURE.1
c Severe exacerbations were defined as events leading to hospitalization, ED visit, or treatment for ≥3 with OCS at ≥2 times the current dose.2
d At Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 10 mL with placebo + SOC (n=107) (LSM difference: 220 mL [95% CI: 90 mL, 340 mL]) in VENTURE.2
e ITT population was unrestricted by minimum baseline EOS or other type 2 biomarkers (eg, FeNO or IgE).2
f The baseline mean OCS dose was 11 mg in the group receiving DUPIXENT and 12 mg in the placebo group.1
g Asthma exacerbation was defined as a temporary increase in OCS dose for at least 3 days.1
TRAVERSE OLE
Primary endpoint results3,4:
86% of patients enrolled from DRI12544, 79% of patients enrolled from QUEST, and 77% of patients enrolled from VENTURE experienced at least
one TEAE up to Week 96 of the OLE period.
DUPIXENT eliminated OCS dose for up to 3 years in the
majority of patients5
79% of patients from VENTURE eliminated their OCS dose4,h
A gradual increase in the number of patients eliminating their OCS dose was observed from 53.3% at Week 0 (n=48) to 59.6% at Week 48 (n=34) to 78.9% at Week 96 (n=15) in the DUPIXENT/DUPIXENT group (TRAVERSE OLE study, secondary endpoint).4,h
TRAVERSE OLE results are descriptive. Definitive conclusions cannot be made.
Data were not multiplicity controlled and there are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.
h OCS reduction was at investigators’ discretion.5
~340,000 asthma patients received 2 or
more OCS bursts in 20236
Two or more OCS bursts in the past year may be a sign of uncontrolled asthma7
- 78% of adult asthma patients who see an asthma specialist received an OCS prescription from someone other than their specialist8
- GINA guidelines state that maintenance OCS should be used as a last resort for asthma treatment because it can lead to side effects7
UNCONTROLLED ASTHMA MAY BE DRIVEN IN PART BY
TYPE 2 INFLAMMATION7
- Up to 84% of adult asthma patients present with type 2 inflammation9,10
ED, emergency department; EOS, eosinophil; FeNO, fractional exhaled nitric oxide; GINA, Global Initiative for Asthma; ITT, intention-to-treat; LSM, least squares mean; OCS, oral corticosteroid; OLE, open-label extension; Q2W, once every 2 weeks; SOC, standard of care; TEAE, treatment-emergent adverse event.
Explore the Safety data and study designs
Dosage and Administration
See the multiple dosage and administration options for patients on DUPIXENT.